SWS Partners Makes New Investment in Guardant Health, Inc. $GH

SWS Partners bought a new stake in Guardant Health, Inc. (NASDAQ:GH) in the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor bought 74,582 shares of the company’s stock, valued at approximately $11,190,000. Guardant Health makes up 2.4% of SWS Partners’ holdings, making the stock its 9th biggest position. SWS Partners owned approximately 0.06% of Guardant Health at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also modified their holdings of the stock. Handelsbanken Fonder AB raised its holdings in shares of Guardant Health by 159.9% during the 2nd quarter. Handelsbanken Fonder AB now owns 301,041 shares of the company’s stock worth $45,165,000 after acquiring an additional 185,200 shares during the period. Bay Colony Advisory Group Inc d b a Bay Colony Advisors purchased a new stake in shares of Guardant Health in the second quarter valued at about $213,000. Allied Private Wealth LLC purchased a new stake in shares of Guardant Health in the second quarter valued at about $72,000. MRA Advisory Group increased its position in Guardant Health by 6.2% during the second quarter. MRA Advisory Group now owns 12,026 shares of the company’s stock worth $1,804,000 after purchasing an additional 706 shares during the last quarter. Finally, GAMMA Investing LLC raised its stake in Guardant Health by 14.5% during the second quarter. GAMMA Investing LLC now owns 965 shares of the company’s stock worth $145,000 after purchasing an additional 122 shares during the period. 92.60% of the stock is owned by institutional investors and hedge funds.

Insider Transactions at Guardant Health

In related news, Director Ian T. Clark sold 14,180 shares of the stock in a transaction dated Tuesday, August 4th. The stock was sold at an average price of $158.92, for a total transaction of $2,253,485.60. Following the transaction, the director owned 2,975 shares of the company’s stock, valued at approximately $472,787. This represents a 82.66% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Chris Freeman sold 63,605 shares of the firm’s stock in a transaction dated Monday, August 10th. The shares were sold at an average price of $169.58, for a total value of $10,786,135.90. Following the transaction, the insider owned 65,374 shares of the company’s stock, valued at $11,086,122.92. This trade represents a 49.31% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last three months, insiders have sold 784,350 shares of company stock worth $106,504,483. 5.60% of the stock is owned by corporate insiders.

Guardant Health Stock Performance

Guardant Health stock opened at $157.21 on Friday. The company has a market capitalization of $21.10 billion, a PE ratio of -45.05 and a beta of 1.60. Guardant Health, Inc. has a fifty-two week low of $53.40 and a fifty-two week high of $176.58. The firm has a 50 day moving average price of $150.40 and a 200 day moving average price of $116.87.

Analysts Set New Price Targets

Several analysts have recently weighed in on the stock. Morgan Stanley increased their price target on shares of Guardant Health from $175.00 to $185.00 and gave the company an “overweight” rating in a research note on Tuesday, August 4th. Sanford C. Bernstein lifted their price target on shares of Guardant Health from $175.00 to $200.00 and gave the company an “outperform” rating in a research report on Thursday, July 2nd. Mizuho upped their price objective on Guardant Health from $175.00 to $200.00 and gave the company an “outperform” rating in a report on Friday, July 31st. Wolfe Research assumed coverage on Guardant Health in a research note on Tuesday, June 2nd. They set an “outperform” rating and a $150.00 target price for the company. Finally, Evercore restated an “outperform” rating and issued a $200.00 target price on shares of Guardant Health in a research report on Monday, July 6th. One research analyst has rated the stock with a Strong Buy rating, twenty-three have assigned a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $183.78.

Guardant Health Company Profile

Guardant Health, Inc is a precision oncology company specializing in blood-based cancer diagnostics. Founded in 2012 and headquartered in Redwood City, California, the company develops non-invasive tests that use circulating tumor DNA (ctDNA) to profile genomic alterations in patients with solid tumors. Guardant Health’s mission is to advance cancer care by providing actionable data to clinicians, pharmaceutical partners and researchers worldwide.

The company’s flagship product, Guardant360, is a next-generation sequencing (NGS) assay designed to detect mutations, copy number variations and select fusions in more than 70 cancer-related genes.